Meju develops HiCardi, a remote patient real-time monitoring platform used for continuous vital-sign tracking. The company has commercial partnerships including a domestic distribution agreement with 동아ST and a memorandum with HL만도 to develop Digital Healthcare Automotive solutions. Meju is expanding HiCardi beyond healthcare into industrial safety monitoring for construction and factory workers and is in final negotiations with a Korean public enterprise for product supply. Financially, Meju reported approximately ₩1.4bn in revenue in 2022, is targeting ₩4.0bn in 2023, and aims for ₩10.0bn in revenue by 2025 to reach breakeven. Its investors have cited the company’s technology, commercialization progress, and growth potential when committing capital.

Total raised

$14M

Funding rounds

1

Latest round

Series B

Latest activity

Nov 2023